Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

Davita IncTrade
ProShares UltraPro S&P500Trade

Price performance (Past 24H)

Key statistics

Davita Inc vs ProShares UltraPro S&P500 — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while ProShares UltraPro S&P500 trades at $154.77 (market cap $5.57B). The key difference: Davita Inc is far larger — about 2× ProShares UltraPro S&P500's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and ProShares UltraPro S&P500 for 29 Days on average.

DVAUPRO
Market Cap
$11.28B$5.57B
Volume
650,2941,824,096
Sector
HealthLeveraged / Inverse
52-Week High
$240.96$157.66
52-Week Low
$103.87$89.29
Typical Hold Time
113 Days29 Days
Enterprise Value
$24.00B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.

The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.

ProShares UltraPro S&P500

UPRO trades at $155.21, down 0.77% on the day, while maintaining a bullish technical stance with strong moving average support. The stock shows neutral momentum oscillators but benefits from positive market sentiment around S&P 500 exposure. Recent news highlights strong corporate earnings growth expectations of 35% for 2026, though concerns exist about concentration risks in top holdings and potential profit growth slowdown to 15% in 2027.

The outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and AI-driven earnings growth, though investors face risks from market concentration, elevated valuations, and potential Federal Reserve policy impacts. Wall Street expects continued gains but acknowledges the need for selective positioning amid changing market dynamics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
UPRO
30% Buy70% Sell
Avg holding period · 29 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About ProShares UltraPro S&P500

UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.

Read more on UPRO →